| Identification | Back Directory | [Name]
Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- | [CAS]
1990504-34-1 | [Synonyms]
IMG-7289 (free base)
Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- | [Molecular Formula]
C28H34FN7O2 | [MOL File]
1990504-34-1.mol | [Molecular Weight]
519.61 |
| Chemical Properties | Back Directory | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (192.45 mM; Need ultrasonic) | [form ]
Oil | [pka]
13.08±0.46(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Bomedemstat is a styrenylcyclopropylamine LSD1 inhibitor, and an antitumor agent. | [in vivo]
Bomedemstat treatment (oral gavage; 45 mg/kg; once daily; 56 d) normalizes or improves blood cell counts, reduces spleen volumes, restores normal splenic architecture, and reduces bone marrow fibrosis[1]. | Animal Model: | Mx-Jak2V617F mice[1] | | Dosage: | 45?mg/kg | | Administration: | Oral gavage; 45?mg/kg; once daily; 56 days | | Result: | Reduced splenomegaly significantly with a few treated mice normalizing their spleen weight, the 56-day course led to partial restoration of lymph follicles and spleen architecture by histological examination. |
| [IC 50]
KDM1/LSD1 | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|